eculizumab biosimilar

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...

South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as ...

Celltrion Healthcare Co. announced on Thursday that its biosimilar anticancer drug Herzuma (active ingredient trastuzumab) for breast and gastr...

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...

South Korean pharmaceutical giant Celltrion Inc. logged record quarterly earnings on the strong performance of its key biosimilar products while exp...

Byooviz, a biosimilar of the macular degeneration treatment Lucentis and made by South Korea’s Samsung Bioepis, has received official design...

South Korea’s biosimilar drugmaker Celltrion group on Monday moved one step closer to the planned combination of its three major affiliates wi...

Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, is rolling out its latest product Epysqli,...

South Korea's Celltrion Healthcare Co. has inked a deal with the US specialty pharmacy chain CarePartners Pharmacy to supply its autoimmune disease ...

South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it has secured approval from the Japanese Ministry of Health, Labou...

Celltrion Inc., a South Korean biopharmaceutical giant, said Monday it will provide biosimilars worth 423.6 billion won ($323.6 million), its larges...

South Korea's Celltrion Healthcare Co. announced on Monday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatm...

The use of data and computing is a new paradigm in the biopharmaceutical industry, reducing the new drug development time and cost, Celltrion Inc. C...

Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, announced on Monday that it signed a partn...

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it has completed a patent agreement with Johnson & Johnson, the m...

South Korean biopharmaceutical company Celltrion Inc. announced on Tuesday that it has received approval from the European Medicines Agency (EMA) fo...

Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea’s Samsung Group, seeks to buy a biosimilar business d...

South Korea's biopharmaceutical company Samsung Bioepis, which was expected to struggle on the US market for biosimilars of Humira, the world's top-...

South Korean biopharmaceutical company Celltrion Healthcare on Monday said it launched the day before on the US market Yuflyma, a biosimilar of the ...

South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...

South Korea’s Celltrion Inc. has put its Japanese Takeda Pharmaceutical Co.'s primary care assets acquired in 2020 on sale as the biosimilar g...

South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA...

South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it plans to beef up its portfolio by applying for regulatory approv...

FRANKFURT – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is looking to gain ground in the ra...

South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...

MILAN – South Korea's biopharmaceutical company Celltrion Inc. is known in Europe for its biosimilar products such as autoimmune disease treat...

South Korean biosimilar giant Celltrion Inc. revealed on Wednesday the highly anticipated clinical phase 1 data for its Actemra biosimilar, CT-P47, ...

South Korea's Samsung Bioepis has received approval in Europe to sell a biosimilar of Soliris, a drug for the treatment of adult and children patien...

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...

South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...